126 related articles for article (PubMed ID: 7985080)
1. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma.
Hara H; Fulton N; Yashiro T; Ito K; DeGroot LJ; Kaplan EL
Surgery; 1994 Dec; 116(6):1010-6. PubMed ID: 7985080
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
[TBL] [Abstract][Full Text] [Related]
3. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
4. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
6. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
7. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.
Volante M; Rapa I; Gandhi M; Bussolati G; Giachino D; Papotti M; Nikiforov YE
J Clin Endocrinol Metab; 2009 Dec; 94(12):4735-41. PubMed ID: 19837916
[TBL] [Abstract][Full Text] [Related]
8. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
[TBL] [Abstract][Full Text] [Related]
9. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
12. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
[TBL] [Abstract][Full Text] [Related]
13. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
14. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Bouras M; Parvaz P; Berger N; Paulin C; Revol A
Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
[TBL] [Abstract][Full Text] [Related]
15. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma.
Wang W; Zhao W; Wang H; Teng X; Wang H; Chen X; Li Z; Yu X; Fahey TJ; Teng L
Ann Surg Oncol; 2012 Jan; 19(1):31-6. PubMed ID: 22033631
[TBL] [Abstract][Full Text] [Related]
16. Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.
Howell GM; Carty SE; Armstrong MJ; Lebeau SO; Hodak SP; Coyne C; Stang MT; McCoy KL; Nikiforova MN; Nikiforov YE; Yip L
Ann Surg Oncol; 2011 Dec; 18(13):3566-71. PubMed ID: 21594703
[TBL] [Abstract][Full Text] [Related]
17. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.
Lin JD; Huang MJ; Juang JH; Chao TC; Huang BY; Chen KW; Chen JY; Li KL; Chen JF; Ho YS
Thyroid; 1999 Dec; 9(12):1227-35. PubMed ID: 10646663
[TBL] [Abstract][Full Text] [Related]
18. Surgical treatment of papillary and follicular thyroid carcinoma.
Lin JD; Jeng LB; Chao TC; Weng HF; Huang HS
Int Surg; 1996; 81(1):61-6. PubMed ID: 8803709
[TBL] [Abstract][Full Text] [Related]
19. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
[TBL] [Abstract][Full Text] [Related]
20. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
Goutas N; Vlachodimitropoulos D; Bouka M; Lazaris AC; Nasioulas G; Gazouli M
Anticancer Res; 2008; 28(1A):305-8. PubMed ID: 18383861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
